- Home
- BGI vs CMMB Comparison
BGI vs CMMB Comparison
Compare BGI & CMMB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | BGI | CMMB |
|---|---|---|
| Founded | 1879 | 2004 |
| Country | Canada | Israel |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 12.8M | 13.0M |
| IPO Year | 2002 | 2023 |
Fundamental Metrics
Financial Performance| Metric | BGI | CMMB |
|---|---|---|
| Price | $0.63 | $1.58 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $25.00 |
| AVG Volume (30 Days) | ★ 60.4K | 40.6K |
| Earning Date | 12-05-2025 | 05-21-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 101.67 |
| EPS | N/A | ★ 0.04 |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | $41.25 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.47 | $0.87 |
| 52 Week High | $1.57 | $3.86 |
Technical Indicators
Market Signals| Indicator | BGI | CMMB |
|---|---|---|
| Relative Strength Index (RSI) | 50.83 | 43.88 |
| Support Level | $0.63 | $1.48 |
| Resistance Level | $0.70 | $1.89 |
| Average True Range (ATR) | 0.06 | 0.16 |
| MACD | 0.01 | -0.03 |
| Stochastic Oscillator | 83.14 | 22.81 |
Price Performance
Historical ComparisonAbout BGI Birks Group Inc.
Birks Group Inc is a part of the leisure industry. The company designs, develops, produces, and retails fine jewelry, timepieces, and gifts. Its operating segments include Retail and Other. The company generates maximum revenue from the Retail segment. Its retail segment consists of retail operations whereby it operates stores in Canada under the Maison Birks, Brinkhaus, Graff, and Patek Phillippe brands. The other segment consists mainly of wholesale business, e-commerce business, and gold exchange business.
About CMMB Chemomab Therapeutics Ltd.
Chemomab Therapeutics Ltd is a clinical-stage biotechnology company, focusing on the discovery and development of therapeutics for fibrosis-related diseases with large unmet needs. The company's candidate, CM-101, is a monoclonal antibody that targets CCL24 and was shown to interfere with the underlying biology of liver, skin, and lung fibrosis using a novel and differentiated mechanism of action. CM-101 has demonstrated the potential to treat multiple severe and life-threatening fibrotic and inflammatory diseases.